Who founded Praeventix?

Praeventix was founded by Douglas Pippin in 2022.

How much funding has Praeventix raised?

Praeventix has disclosed $16.7M raised across 3 rounds.

Where is Praeventix headquartered?

Praeventix is headquartered in Exton, US.

Praeventix

Exton, US · Founded 2022 · Delaware corporation

Find your way into Praeventix

123 people in our graph share verified history with the Praeventix team — schools, employers, funds. One of them is your warm intro.

Patrick Enrightunlockedknows Heidi Kempinski · together at Zenas Biopharma (overlapped)

×5knows the team · via Zenas Biopharma

×4knows the team · via Dartmouth College

×2knows the team · via Aegle Therapeutics

Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.

Biotech Digital Health

Founders & leadership

Praeventix was founded in 2022 by Douglas Pippin.

Douglas Pippin President & Founder, PIDouglas Pippin is President and Founder of Praeventix, a biopharmaceutical company developing serotonergic therapeutics, and has previously founded or co-founded multiple companies in drug discovery, dermatology, and green chemistry; his drug research background spans 15+ years focused on structure-based design and G-protein-coupled receptor ligands, with prior work contributing to a $500M+ pharmaceutical alliance and an anti-oncogenic compound that reached Phase II development.

Heidi Kempinski ExecutiveHeidi Kempinski is Executive Officer and Director at Praeventix, an early-stage biopharmaceutical company developing serotonergic therapeutics for conditions including atopic dermatitis, inflammatory bowel disease, and cocaine use disorder. She has held senior executive roles in startup and growth-stage biopharmaceutical organizations, with experience in drug development, R&D operations, corporate strategy, and mergers and acquisitions.

Leon O. Moulder, Jr.Executive

KempinskiCEO

MoulderExecutive Chair

Board

Robert S. HankinBoard director

Leonard O. Moulder, Jr.Board director

Reported raises · per SEC filings

Form D private placements

$16.7M disclosed across 3 rounds · 2022–2026

▶$5.6MraisedSep 2026 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Douglas A. Pippin, PhDExecutive Officer, Director
Leon O. MoulderDirector
Heidi KempinskiExecutive Officer, Director
Robert S. HankinDirector

Offering amount: $5.6M
Amount sold: $5.6M
First sale: Feb 2026
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6.8MraisedMay 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Heidi KempinskiExecutive Officer, Director
Douglas A. PippinExecutive Officer, Director
Robert S. HankinDirector
Leonard O. Moulder, Jr.Director

Offering amount: $6.8M
Amount sold: $6.8M
First sale: May 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.3MraisedMay 2024 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Douglas A. PippinExecutive Officer, Director
Leon O. Moulder, Jr.Director

Offering amount: $4.3M
Amount sold: $4.3M
Proceeds to insiders: $1.3M
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Praeventix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Praeventix do?: Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.
Who founded Praeventix?: Praeventix was founded by Douglas Pippin in 2022.
How much funding has Praeventix raised?: Praeventix has disclosed $16.7M raised across 3 rounds.
Where is Praeventix headquartered?: Praeventix is headquartered in Exton, US.